The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CPRX | -9.9% | +534.12% | +44.69% | +251% |
| S&P | +13.96% | +91.24% | +13.85% | +393% |
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.
The drugmaker confirmed there's a strong market for two of its treatments.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $148.39M | 15.3% |
| Gross Profit | $116.39M | 16.3% |
| Gross Margin | 78.44% | 0.7% |
| Market Cap | $2.41B | 2.2% |
| Market Cap / Employee | $13.32M | 0.0% |
| Employees | 181 | 8.4% |
| Net Income | $52.78M | 20.3% |
| EBITDA | $75.68M | 25.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $689.89M | 56.0% |
| Accounts Receivable | $106.41M | 82.6% |
| Inventory | 28 | 40.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.46M | -14.8% |
| Short Term Debt | $0.43M | 8.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 23.86% | -0.2% |
| Return On Invested Capital | 26.20% | -2.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $32.44M | -55.3% |
| Operating Free Cash Flow | $32.44M | -55.5% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 15.95 | 15.48 | 13.17 | 11.50 | -32.22% |
| Price to Book | 3.77 | 4.03 | 3.33 | 2.82 | -21.49% |
| Price to Sales | 5.36 | 5.76 | 4.96 | 4.33 | -20.02% |
| Price to Tangible Book Value | 5.03 | 5.13 | 4.09 | 3.36 | -29.91% |
| Price to Free Cash Flow TTM | 11.02 | 11.51 | 10.07 | 10.67 | -19.50% |
| Enterprise Value to EBITDA | 29.31 | 34.34 | 27.96 | 24.00 | -29.38% |
| Free Cash Flow Yield | 9.1% | 8.7% | 9.9% | 9.4% | 24.22% |
| Return on Equity | 29.4% | 29.1% | 28.5% | 27.5% | -2.73% |
| Total Debt | $3.19M | $3.09M | $2.99M | $2.89M | -11.97% |
No podcast episodes available.
CPRX earnings call for the period ending September 30, 2021.
CPRX earnings call for the period ending June 30, 2021.
CPRX earnings call for the period ending March 31, 2021.
CPRX earnings call for the period ending September 30, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
